. . . "N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine"@en . . . . "(2S)-2-(Butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid"@en . "Tirofiban"@en . . . . . . . . . . "Tirofiban"@en . "Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation."@en . "* 22 to 42 L"@en . . . . . "Tirofibanum"@en . "* 213 - 314 mL/min [Healthy subjects] * 152 - 267 mL/min [patients with coronary artery disease]"@en . "For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy."@en . . . . . . . . . . . "approved"@en . " "@en . . "George Roby Thomas, Dawson James Reimer, Albert D. Friesen, \"TRANSDERMAL PHARMACEUTICAL PREPARATION AND ADMINISTRATION OF TIROFIBAN.\" U.S. Patent US20120029447, issued February 02, 2012."@en . . "Humans and other mammals"@en . . "It is cleared from the plasma largely by renal excretion, with about 65% of an administered dose appearing in urine and about 25% in feces, both largely as unchanged tirofiban."@en . . . . . . . . . "Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of tirofiban."@en . . . . . . . "2 hours"@en . . . . . "144494-65-5"@en . . . . . . "65%"@en . . . . .